Key Updates in Non-Small Cell Lung Cancer From ASCO 2026

Published Date: 25 Jun 2026

Updates in NSCLC from ASCO 2026 include phase 3 results for selpercatinib, ivonescimab, and sac-TMT, plus emerging data for neladalkib in ALK+ disease and sunvozertinib in the frontline setting.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Mental health risk persists years after cancer diagnosis

2.

Breast cancer prevention: How nurse practitioners and physician assistants can help

3.

For treatment, the majority of cancer patients choose complementary therapies.

4.

Cancer mortality continuing to decline, says report

5.

Doctors say lung cancer is still the deadliest cancer, but hope is growing


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot